Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Roopa Industries Limited operates in the pharmaceuticals sector, focusing on the production of generic medications primarily for the Indian market. The company has a competitive edge due to its established supply chain and cost-effective manufacturing processes, which allow it to maintain lower prices compared to larger multinational competitors.
Roopa Industries generates revenue through the sale of generic drugs, which are priced competitively due to lower production costs. The company benefits from economies of scale in its manufacturing processes and has established relationships with distributors across India, enhancing its market reach.
Changes in regulatory policies affecting generic drug approvals
Fluctuations in raw material prices impacting production costs
Market share shifts in the Indian pharmaceutical sector
New product launches or patent expirations in key therapeutic areas
Regulatory changes that could affect generic drug pricing and approvals
Technological advancements in drug development that could outpace current offerings
Intensifying competition from larger pharmaceutical companies entering the generic space
Emergence of new generic manufacturers in India and abroad
High debt-to-equity ratio (1.76) indicating potential liquidity issues
Low net margin (0.1%) limiting financial resilience
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP growth.
Higher interest rates can increase financing costs for Roopa Industries, potentially impacting capital expenditures and profitability. However, the direct impact on demand for pharmaceuticals is limited.
minimal - The company does not heavily rely on credit for operations, but high debt levels could affect its financial flexibility.
value - Investors may be drawn to the stock due to its low price-to-sales ratio (0.3x), indicating potential undervaluation.
moderate - The stock has shown some volatility with a 1-year return of -11.2%, reflecting market uncertainties.
